Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and Victoria Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120700BIZWIRE_USPR_____20260312_BW036459) on March 12, 2026, and is solely responsible for the information contained therein.